The authors analyze the critical points and the results of the paper OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer,published by Aghajanian C et al on 10 june 2012 in J Clin Oncol
Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View / Tomao, Federica; Tomao, Silverio; Panici, P. B.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:1(2013), pp. 166-167. [10.1200/jco.2012.44.6237]
Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View
TOMAO, FEDERICA;TOMAO, SILVERIO;P. B. Panici
2013
Abstract
The authors analyze the critical points and the results of the paper OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer,published by Aghajanian C et al on 10 june 2012 in J Clin OncolFile allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.